Search Results
Found 2 results
510(k) Data Aggregation
(324 days)
The Pro X OTC 5 is an Over-The-Counter device intended for use in the treatment of facial wrinkles. It is for people with wrinkles on their face and who have Fitzpatrick skin types I, II and/or III.
The Pro X OTC 5 is an Over-the-Counter device intended for use in the treatment of facial wrinkles. Facial wrinkles are lines on the skin that appear as you age. Facial wrinkles can appear anywhere on the face, such as on the forehead, around the eyes, and by the mouth. The Pro X OTC 5 is for people with wrinkles on their face and who have Fitzpatrick skin types I, II, and/or III.
The Pro X OTC 5 uses known LED light therapy technology. A combination of red light (620-630mm) and infrared light (855nm) is emitted. To use the Pro X OTC 5 device, users place the lightweight mask over the face and then press the "On" button on the controller to start treatment. The device will automatically turn off after each treatment cycle.
The Pro X OTC 5 device is designed to be used for 30 treatment sessions. The full treatment regimen for facial wrinkles includes 60 individual treatments, therefore purchase of two (2) devices is needed to receive the full treatment regimen.
Here's an analysis of the provided text regarding the acceptance criteria and the study proving the device meets them:
Device Name: Pro X OTC 5 Light Therapy Device
Intended Use: Treatment of facial wrinkles in people with Fitzpatrick skin types I, II, and/or III.
1. Table of Acceptance Criteria and Reported Device Performance
The document does not explicitly state pre-defined "acceptance criteria" with numerical thresholds for clinical performance. Instead, it aims to demonstrate substantial equivalence to predicate devices and effectiveness through a clinical study. The primary measure of effectiveness is improvement in Fitzpatrick Wrinkle and Elastosis Scale scores.
| Acceptance Criteria (Implied) | Reported Device Performance |
|---|---|
| Clinical Effectiveness: | |
| Improvement in facial wrinkles (as measured by Fitzpatrick Wrinkle and Elastosis Scale). | Treatment Group (n=30): |
| Physician 1: | |
| - Baseline mean grade: 5.10 | |
| - 8-week mean grade: 3.86 (1.24 point improvement) | |
| - 20-week post-treatment mean grade: 3.83 (1.28 point improvement from baseline) | |
| Physician 2: | |
| - Baseline mean grade: 5.03 | |
| - 8-week mean grade: 3.83 (1.21 point improvement) | |
| - 20-week post-treatment mean grade: 3.90 (1.14 point improvement from baseline) | |
| Individual Improvement: Each subject in the treatment group demonstrated at least 1 point improvement (baseline vs. 20-weeks post-treatment). | |
| Statistical Significance: Treatment Group showed statistically significant improvement (p<0.001) at all evaluation periods and statistically outperformed the Control Group. | |
| Safety: | Conforms to IEC 60601-1 3rd edition, IEC 60601-1-2, and IEC 62471. |
| Usability: | Users can understand labeling and use the device appropriately. |
| Self-Selection: | External packaging provides sufficient information for users to self-select. |
2. Sample Size Used for the Test Set and Data Provenance
- Sample Size for Clinical Study: 50 subjects.
- Treatment Group: 30 subjects
- Control Group: 20 subjects
- Data Provenance: The document does not explicitly state the country of origin of the data. It is a prospective clinical study (subjects were assigned to groups and followed over time with interventions).
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications
- Number of Experts: Two (2) independent, blinded, licensed physicians.
- Qualifications: Licensed physicians. Specific experience (e.g., years of experience or specialization in dermatology) is not provided.
4. Adjudication Method for the Test Set
The document does not describe an adjudication method for the physicians' evaluations. It states that photographs were evaluated by "two independent, blinded, licensed physicians." It then reports separate mean scores for "Physician 1" and "Physician 2," implying their individual assessments were used in the statistical analysis, rather than a consensus or adjudicated single score.
5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study Was Done, and Effect Size
- Was an MRMC study done? No, not in the typical sense of comparing human reader performance with and without AI assistance. This study evaluated the effectiveness of a device (Pro X OTC 5) itself, with physicians acting as evaluators of the clinical outcome, not as readers of AI output.
- Effect Size: Not applicable in this context. The study did not involve AI assistance for human readers. It reported the device's treatment effect on wrinkle scores.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done
- Not applicable. The Pro X OTC 5 Light Therapy Device is a physical medical device (mask with LED lights) used by the patient, not a software algorithm. Therefore, there is no "standalone algorithm performance" to evaluate. The study assesses the device's efficacy when used by subjects.
7. The Type of Ground Truth Used (Expert Consensus, Pathology, Outcomes Data, etc.)
- Type of Ground Truth: The ground truth for the effectiveness of the device (i.e., the presence and severity of facial wrinkles and their changes) was established by the independent evaluation of standardized facial photographs by two licensed physicians using the 9-point Fitzpatrick Wrinkle and Elastosis Scale. This can be considered a form of expert assessment/consensus (though their scores were reported individually rather than adjudicated to a single "truth"). Outcomes data (i.e., direct patient experience/satisfaction) is not explicitly detailed as a primary endpoint beyond the physician evaluations.
8. The Sample Size for the Training Set
- Not applicable. The Pro X OTC 5 is a light therapy device, not an AI/machine learning algorithm that requires a training set of data. Its performance is based on the physical properties of the emitted light and its biological interaction with skin.
9. How the Ground Truth for the Training Set Was Established
- Not applicable, as there is no training set for this type of device.
Ask a specific question about this device
(245 days)
The illuMask Acne Light Therapy Mask is intended to emit energy in the red and blue region of the spectrum, specifically indicated to treat mild to moderate acne on the face.
The IlluMask Acne Light Therapy device uses known LED light therapy technology for the treatment of mild to moderate acne. A combination of red light (630mm) and blue light (445nm) is emitted. Users place the lightweight mask over the face press the On button on the controller button to start treatment. The device will automatically turn off after each treatment, and there is a total of 30 treatments.
Here's a breakdown of the acceptance criteria and the study that demonstrates the illuMask Acne Light Therapy Mask meets these criteria, based on the provided 510(k) summary:
1. Table of Acceptance Criteria and Reported Device Performance
The provided document doesn't explicitly list "acceptance criteria" as a separate table. However, it presents the "Treatment Period Results" as evidence of the device's efficacy, which effectively serve as the performance benchmarks the device achieved.
| Performance Metric (Implicit Acceptance Criteria) | Reported Device Performance (Treatment Period Results) |
|---|---|
| Decrease in inflammatory acne lesions | 82.8% decrease |
| Decrease in non-inflammatory acne lesions | 71.2% decrease |
| Improvement in acne severity (FDA Global Acne Severity Scale) | 50% improvement (median movement of 2 points) |
| Reduction in total acne lesions (independent doctor evaluation, Week 4) | 36% reduction |
| Reduction in total acne lesions (independent doctor evaluation, Week 8) | 65.8% reduction |
| Patient compliance, satisfaction, and questionnaire grading | Highly favorable |
| Serious adverse events | None reported |
2. Sample Size Used for the Test Set and Data Provenance
- Test Set Sample Size:
- Clinical Study: 30 patients were initially enrolled for both the Washout and Treatment Periods. 27 of 30 subjects completed each period.
- Usability Study: 35 participants.
- Self-Selection Study: 47 randomly selected participants.
- Data Provenance: The document does not explicitly state the country of origin for the clinical study data. It describes it as an "IRB (Institutional Review Board) approved 12-week clinical study," suggesting a formal clinical investigation. The Self-Selection Study was conducted "in a typical retail / shopping mall environment," implying a US-based setting given the context of FDA submission. The Usability Study was conducted by an "independent testing group." The studies appear to be prospective.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications
- Clinical Study:
- Principal Investigator: Conducted in-person clinical grading for acne counts and FDA Global Acne Severity Scale, and recorded adverse events. Qualifications are not explicitly detailed but implied to be a medical professional ("physician investigator").
- Independent Doctors: Two independent doctors conducted physician grading on the clinical photographs. Their specific qualifications (e.g., "dermatologist with 10 years of experience") are not provided, but they are described as "independent doctors."
4. Adjudication Method for the Test Set
- For the clinical photographs, "an average of the two independent doctor evaluations" was used to report the reduction in total acne lesions. This suggests a form of averaging or consensus between two independent readers. The phrase "adjudication" is not explicitly used, but the averaging of independent readings serves a similar purpose.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done
The provided summary does not describe a formal Multi-Reader Multi-Case (MRMC) comparative effectiveness study comparing human readers with and without AI assistance. The study described is a clinical trial evaluating the device's efficacy in treating acne, not comparing diagnostic accuracy or efficiency with AI.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done
The illuMask is a light therapy device, not an AI algorithm. Therefore, the concept of a "standalone algorithm" performance study is not applicable to this device. The clinical study assessed the device's direct therapeutic effect on patients.
7. The Type of Ground Truth Used
- Clinical Study Ground Truth: The ground truth for the clinical study was established through a combination of:
- Expert Clinical Assessment: In-person grading by the principal investigator using metrics like the FDA Global Acne Severity Scale and lesion counts.
- Expert Consensus on Photography: Two independent doctors evaluating standardized clinical photography in a blinded and randomized manner.
- Patient Self-Evaluation: Subjective assessments by patients on 14 attributes.
- Outcomes Data: Reduction in lesion counts and improvement in acne severity over time.
8. The Sample Size for the Training Set
The illuMask is a light therapy device, not a machine learning model. Therefore, there is no training set in the context of AI or algorithm development. The "training" in this context refers to the development and refinement of the physical device and its instructions, which was informed by the Usability and Self-Selection studies but not in the sense of an algorithm training set.
9. How the Ground Truth for the Training Set Was Established
As stated above, this device does not involve a machine learning algorithm, and thus, no ground truth for a training set was established. The Usability and Self-Selection Studies helped refine the device's instructions and packaging to ensure ease of use and understanding by the target audience, which could be considered an iterative design and development process rather than algorithmic training.
Ask a specific question about this device
Page 1 of 1